Amradeep Industries Limited Overview
Amerise Biosciences Limited is a 42-year-old BSE-listed Gujarat company that began life as Amstar Laminates. It drifted through laminates, commodity trading and castor-seed trading as Amradeep Industries, and was renamed in 2021 to signal a move into "biosciences". In practice the listed entity has had no meaningful operations for most of the past decade. Revenue was zero in most years. The one exception was a single INR 9.58 crore trading year in FY2026's predecessor period, FY2022. The balance sheet holds about INR 7.4 crore of total assets, mostly investments and other current assets, with no debt and no fixed assets. Net worth of about INR 5.4 crore roughly matches the market value. The company has no identified promoter, a retail-dominated register of about 33,000 holders, and frequent changes to its key managerial personnel and website domains. Some aggregators link it to Amerise Pharmaceuticals Pvt Ltd, an Ahmedabad pharmaceutical development firm, but no filed corporate relationship has been verified. The investment case rests on corporate action, not on operations.
What the company does today. On the evidence available, the listed company does not run an identifiable operating business:
-
Tickertape describes it as currently inactive with no revenue generation.
-
Kotak Neo's profile, drawing on the company's disclosures, says that in FY2025 the company carried out no business activities because of a "financial crisis".
-
Screener's legacy profile describes it as non-operational for several years.
Company's own description. Exchange and broker profiles, which derive from company filings, describe the history as follows. The company was incorporated in 1984 as Amstar Laminates, described as a maker of construction and agricultural equipment. It was renamed Amradeep/Amardeep Industries on 29 October 2002 and Amerise Biosciences in 2021. It was originally engaged in commodity trading and added castor-seed trading in FY2007.
The 2009–10 annual report on BSE refers to the castor-seed trading environment in Gujarat, which is consistent with this history. The description of "construction and agricultural equipment" manufacturing is inconsistent with the "Laminates" name and with Screener's description of decorative boards and laminate sheets. Both versions circulate in aggregator databases, and the discrepancy is unresolved in the sources reviewed.
That is the website of Amerise Pharmaceuticals Pvt Ltd, a private company established in 2018. It focuses on NDA, 505(b)(2) and complex formulations (injectables, ophthalmics, oral dosage forms) and has offices in Cranbury (New Jersey, USA), Buckshaw Village (Lancashire, UK) and Bodakdev (Ahmedabad, India).
The listed company reports no subsidiaries in available data, and its balance sheet carries no fixed assets, laboratories or R&D spend. It may be a naming coincidence or an aggregator misattribution, or it may signal an intended but undisclosed relationship.
Business model and revenue model. No recurring revenue model exists.
Screener's quarterly data show small "sales" in each quarter of FY2026 (0.06, 0.07, 0.04 and 0.08), which sum to about INR 0.25 crore. The annual statement instead books about INR 0.26 crore as other income and zero as sales. This is a classification discrepancy between quarterly and annual presentation. Either way, the income most likely reflects interest or financing income on loans and advances, not trading.
Value-chain position, customers and end-markets. Not applicable or not publicly disclosed. Data vendors classify the company in very different industries:
-
Plastic Products – Industrial (Screener, MarketsMojo)
-
Finance – Investment (StockEdge, MoneyWorks4Me)
-
Other Agricultural Products (Research360)
-
Pharmaceuticals (Emkay)
-
Blank-check company (MarketScreener)
This spread is itself diagnostic of an entity without a defined business.
Independent characterisation. Amerise Biosciences is best described as a listed shell with a small treasury of investments and loans. It is funded entirely by legacy equity of INR 6.61 crore, with accumulated losses of about INR 1.2 crore. Its main economic asset is its BSE listing and a large, fragmented retail shareholder base. The FY2022 burst of INR 9.58 crore of trading revenue coincided with an 84-fold rise in shareholder count, and the 2021 rename to "biosciences" came without any disclosed pharmaceutical assets. Taken together, these show a listed vehicle whose narrative has shifted without the operations to support it.
Strategy
Stated strategy. No corporate strategy statement, investor presentation, investor day or earnings call exists in public sources. The 2021 renaming to "Amerise Biosciences" is the only implicit strategic signal, pointing to biosciences or pharmaceuticals. In five years since then, the company has disclosed no supporting initiative: no acquisition, licence, capital raise, plant, R&D spend or regulatory filing.
Initiatives in the last 24 months (Oct 2024 – Oct 2026).
Transformation programmes, partnerships, ESG commitments, cost programmes: none disclosed. Medium-term financial targets or guidance: none issued.
Products & Services
Pricing models, flagship offerings, launch years: not publicly disclosed or not applicable. The listed company has no named brands, platforms or active product lines. The patents and applications that Amerise Pharmaceuticals' website lists belong to that private company and are not attributable to the listed entity on current evidence. Examples include an anti-vertigo compound (WO2022091118) and a stable non-steroidal antiandrogen composition.
Product Portfolio
| Segment | Product / service | Description | Status | Source |
|---|---|---|---|---|
Single segment | Decorative boards and laminate sheets (historical) | Laminates manufacturing and trading under the Amstar Laminates identity | Discontinued; non-operational for years | Screener legacy profile |
Single segment | Commodity trading (historical) | General commodity trading | Discontinued or dormant | Company profiles |
Single segment | Castor-seed trading (historical, FY2007 onward) | Trading in Gujarat-grown castor seeds | Dormant; no revenue since FY2022 except trivial amounts | FY2010 annual report; profiles |
Single segment | Construction and agricultural equipment (as described in profiles) | Profiles say the company was set up to make such equipment | No evidence of production in reviewed financials (zero fixed assets since at least FY2015) | Company profiles |
Single segment | "Biosciences" / pharmaceutical development | Implied by the 2021 rename. Screener links the description to Amerise Pharmaceuticals Pvt Ltd (NDA, 505(b)(2), complex injectables, ophthalmics, oral forms) | — | Screener; amerisepharma.com |
Single segment | Financing / treasury income | Other income of INR 0.19 crore (FY2025) and INR 0.26 crore (FY2026), possibly interest on loans and advances | Current, sole income source | Screener |
Financial Narrative
Source for all tables: Screener.in standalone financials compiled from BSE filings, FY2022–FY2026, INR crore unless stated. Ratios marked "derived" are arithmetic computations from these figures, not vendor-reported values.
Income statement
Gross profit is not reported separately; Screener aggregates cost of goods into total expenses. Diluted EPS equals basic EPS, since no dilutive instruments are disclosed.
Margins
Blank cells mean not meaningful (zero revenue denominator). The revenue CAGR from FY2022 to FY2026 is not computable because FY2026 revenue was zero. Screener reports 10-year, 5-year and 3-year sales CAGRs as blank and TTM sales growth as –24%.
Balance sheet
Additional notes on the balance sheet:
Cash and equivalents: Not separately disclosed in reviewed aggregates for FY2022–FY2025. Zerodha's data show net debt of –INR 0.59 crore as of March 2026, which implies cash of about INR 0.59 crore with zero debt. This is consistent with Screener's FY2026 net cash flow of +INR 0.57 crore.
Short- and long-term debt split: Not disclosed. The FY2022–FY2023 borrowings of INR 0.08–0.09 crore were repaid in FY2024.
Working capital: Screener reports working-capital days of –1.91 (FY2022), –1,460 (FY2023) and –182.5 (FY2024); FY2025–FY2026 are not computable on zero revenue.
Ratios
The following ratios are not meaningful or not computable:
ROIC: not separately computable; it approximates ROCE, since the company has no debt.
Interest coverage: interest expense is zero. Screener's automated flag of "low interest coverage" is a mechanical artefact.
Net debt/EBITDA: negative EBITDA and net cash.
Current ratio: the classification of other assets and liabilities between current and non-current is not disclosed. A crude derived proxy of other assets divided by other liabilities gives about 1.8x for FY2026.
Commentary on trends, inflections and drivers
FY2022 is the sole operating inflection. Revenue of INR 9.58 crore against expenses of INR 9.03 crore gave a 5.7% margin, the pattern of pass-through trading. Year-end other liabilities of INR 6.27 crore and other assets of INR 7.30 crore swelled the balance sheet to INR 11.99 crore. Both unwound within twelve months, and FY2023 revenue was INR 0.01 crore. The episode coincided with the rename to Amerise Biosciences and an 84-fold rise in the shareholder count, from 175 to 14,701. The counterparties and the nature of the traded goods are not disclosed in reviewed sources. That opacity is a key diligence point.
FY2023–FY2024 were dormant years. The company ran annual cash burn of about INR 0.13–0.17 crore to cover listing, audit, RTA and compliance costs, and reserves declined slowly.
FY2025–FY2026 brought a shift to treasury income. The P&L turned marginally positive (INR 0.01 crore and INR 0.02 crore) only because other income of INR 0.19 crore and INR 0.26 crore covered running costs. The cash-flow pattern shows large offsetting movements: +3.07 operating and –3.07 investing in FY2025, then –1.06 operating and +1.63 investing in FY2026. Alongside the rise and fall in other liabilities (INR 3.08 crore in FY2025, INR 2.03 crore in FY2026), this is consistent with funds received and lent or invested on behalf of others, such as inter-corporate deposits or advances. The quality of those receivables and investments is undisclosed and is the main balance-sheet risk.
Q1 FY2027 (June 2026 quarter) reverted to a pure loss of INR 0.08 crore, with zero income and expenses of INR 0.08 crore. This shows that the FY2026 profit depended on treasury income that has not recurred.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue from operations, single segment (INR Cr) | 0.04 | 0.00 | 0.00 |
Other income (INR Cr) | 0.00 | 0.19 | 0.26 |
Pre-tax profit (INR Cr) | -0.15 | 0.01 | 0.02 |
Share of total revenue from operations (%) | 100 | 0 | 0 |
Revenue by Segment
| Metric | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.19 | 0.06 | 0.07 | 0.04 | 0.08 | 0.00 |
Expenses (INR Cr) | 0.07 | 0.04 | 0.06 | 0.02 | 0.05 | 0.03 | 0.02 | 0.08 | 0.07 | 0.11 | 0.03 | 0.02 | 0.08 |
Net profit (INR Cr) | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 9.58 | 0.01 | 0.04 | 0.00 | 0.00 |
Other income (INR Cr) | 0.00 | 0.00 | 0.00 | 0.19 | 0.26 |
Total expenses (INR Cr) | 9.03 | 0.13 | 0.19 | 0.18 | 0.24 |
Operating profit / EBITDA excl. other income (INR Cr) | 0.55 | -0.12 | -0.15 | -0.18 | -0.24 |
Depreciation (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pre-tax income (INR Cr) | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 |
Tax (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net income (INR Cr) | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 |
EPS basic (INR) | 0.08 | -0.02 | -0.02 | 0.00 | 0.00 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Operating margin (%) | 5.74 | -1,200 | -375 |
Net margin (%, derived) | 5.74 | -1,200 | -375 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
Reserves and surplus (INR Cr) | -0.97 | -1.09 | -1.23 | -1.23 | -1.21 |
Total equity (INR Cr, derived) | 5.64 | 5.52 | 5.38 | 5.38 | 5.40 |
Borrowings, total (INR Cr) | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 |
Other liabilities (INR Cr) | 6.27 | 0.04 | 0.01 | 3.08 | 2.03 |
Total assets (INR Cr) | 11.99 | 5.65 | 5.39 | 8.46 | 7.43 |
Fixed assets incl. CWIP (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments (INR Cr) | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
Other assets (INR Cr) | 7.30 | 1.08 | 3.12 | 6.08 | 3.66 |
Goodwill and intangibles (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operations (INR Cr) | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
Cash from investing (INR Cr) | -0.15 | 0.13 | 0.27 | -3.07 | 1.63 |
Cash from financing (INR Cr) | 0.08 | 0.01 | -0.09 | 0.00 | 0.00 |
Net cash flow (INR Cr) | -0.01 | 0.00 | 0.01 | 0.00 | 0.57 |
Capex (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (INR Cr) | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROCE (%, Screener) | 10.18 | -2.12 | -2.73 | 0.19 | 0.37 |
ROE on average equity (%, derived) | 10.3 | -2.2 | -2.8 | 0.19 | 0.37 |
ROA on year-end assets (%, derived) | 4.6 | -2.1 | -2.8 | 0.1 | 0.3 |
Debt to equity (x, derived) | 0.01 | 0.02 | 0 | 0 | 0 |
Asset turnover (x, derived on year-end assets) | 0.80 | 0.00 | 0.01 | 0 | 0 |
Cash conversion cycle (days, Screener) | 236.98 | 0 | 0 | — | — |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations, all geographies (INR Cr) | 0.04 | 0.00 | 0.00 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Current price (INR) | 0.81 | Screener, 19 Oct 2026 |
52-week high / low (INR) | 1.03 / 0.50 | Screener / IIFL, 2026 |
1-year price change (%) | 47 | Screener stock-price CAGR, Oct 2026 |
3-year price CAGR (%) | 12 | Screener, Oct 2026 |
5-year price CAGR (%) | -12 | Screener, Oct 2026 |
10-year price CAGR (%) | -4 | Screener, Oct 2026 |
Capital Markets
| Metric | FY2026 |
|---|---|
Share price near fiscal year end (INR; Mar-2024 n/a, Mar-2025 n/a, Mar-2026 27-Mar close) | 0.62 |
Valuation Multiples
| Multiple | Amerise Biosciences | Comment |
|---|---|---|
P/B | 0.99x | Screener |
EV (INR Cr, derived) | About 4.76 | Market cap 5.35 less March 2026 net cash of 0.59 |
EV/Sales (TTM, derived) | About 25x | On TTM "sales" of INR 0.19 crore (quarterly series) |
Peer P/B (BAMPSL Securities, Equitymaster) | About 0.9–1.0x | Comparable |
Analyst Conclusions
Management guidance: none issued. Consensus growth expectations: none, as there is no coverage.
Bull case
-
Clean shell at book value. A debt-free listed vehicle trading at about 1x book (INR 5.4 crore) with a 33,000-holder register is a low-cost listing route. Any reverse merger or business injection would likely re-rate it well above book.
-
Signs of a shareholder group building a position. SAST Reg. 29(1)/29(2) disclosures by Snehjeev Ventures & PACs indicate a group crossing 5% and adding to its stake, a common precursor to an open offer or change of control.
-
Governance reset. A new Company Secretary (Apr 2026) and WTD & CFO (Sep 2026) could herald fuller disclosure and a defined strategy, potentially including the long-signalled biosciences pivot.
Bear case
-
No business, five years after the "biosciences" rename. Zero fixed assets, zero R&D, zero annual revenue in FY2025–FY2026, and an admitted absence of business activity in FY2025.
-
Book value of uncertain quality. About INR 7.4 crore of investments and other assets is unitemised. The two-way cash-flow swings (±INR 3 crore in FY2025) and the swelling and contraction of other liabilities look like pass-through financing, so book value could be impaired.
-
Surveillance and governance red flags. GSM/ASM designation, 0% promoter holding, three KMP changes in eight months, repeated domain changes, and the pattern of a FY2022 revenue spike alongside an 84-fold rise in shareholder count all point to elevated regulatory and investor-protection risk.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q2 FY2027 results (September quarter) | By mid-Nov 2026 (trading window closed from 1 Oct 2026) | Whether treasury income resumes or losses continue |
| Itemised FY2026 annual report notes (investments, loans, related parties, contingent liabilities) | Already filed; needs review | Asset quality is the core valuation question |
| Any Reg. 30 disclosure of business acquisition, preferential issue or scheme of arrangement | Unscheduled | Would define the post-shell strategy |
| SAST filings / open offer by Snehjeev Ventures & PACs or others | Unscheduled | A change in control would be the main re-rating trigger |
| GSM/ASM status changes | Ongoing | Liquidity and suspension risk |
| Disclosure of any relationship with Amerise Pharmaceuticals Pvt Ltd | Unscheduled | Would validate or refute the biosciences narrative |
| Further KMP or board changes; website stability | Ongoing | Governance signal |
Concluding analyst verdict
Amerise Biosciences Limited, the former Amradeep Industries Limited, should not be analysed as an operating company. It is a 1984-vintage Gujarat entity that has moved through laminates, commodity trading and castor seeds. It took a "biosciences" name in 2021 but has not acquired any biosciences assets, revenue, staff or R&D in the five years since. Its financial statements describe a dormant shell:
-
equity of about INR 5.4 crore built on INR 6.61 crore of legacy capital less accumulated losses
-
zero debt and zero fixed assets
-
annual running costs of INR 0.2 crore, offset in FY2025–FY2026 by treasury-type income that did not recur in Q1 FY2027
The single year of real activity, FY2022's INR 9.58 crore of thin-margin trading, coincided with the rename and an extraordinary influx of retail shareholders. Its counterparties remain undisclosed.
The valuation is anchored to book: at INR 0.81 the market cap of INR 5.35 crore is about 0.99x net worth. Downside therefore depends on the quality of roughly INR 7.4 crore of investments and other assets that public sources do not itemise. Upside depends entirely on corporate action, such as a change of control, a reverse merger or a real business injection. The SAST disclosures by Snehjeev Ventures & PACs and the 2026 KMP reconstitution are the only tangible hints that such action may be in prospect, and neither confirms it.
Governance is the binding constraint. The company has no promoter, is under BSE GSM/ASM surveillance, has seen rapid KMP turnover, and has changed its website domain repeatedly.
Verdict: Not investable on fundamentals; speculative special-situation only. The stock warrants monitoring for Regulation 30 disclosures of corporate action, but any position is effectively a bet on an unannounced transaction by unidentified parties. Prudent investors should first obtain the full FY2026 annual report notes, particularly on investments, loans, related-party transactions and contingent liabilities.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior / other roles | Source |
|---|---|---|---|---|
Albert Hines | Whole-time Director & CFO | Appointed at AGM, 24 Sep 2026 | — | BSE AGM outcome (Screener summary) |
Kelash Bunkar | Independent Non-Executive Director | Start date not disclosed | — | Blinkx board listing |
Dineshkumar Tribhovanbhai Rathod | Former Whole-time Director, Director (Finance) & CFO | 2021 – 2 Feb 2026 | Independent Non-Executive Director at Interface Financial Services Ltd, Amraworld Agrico Ltd and Suncare Traders Ltd (all from 22 Nov 2021) | MarketScreener; Blinkx |
Company Secretary & Compliance Officer | — | Changed on 15 Apr 2026 (resignation plus new appointment) | Names not disclosed in reviewed sources | Emkay / Dion Global |
Mahendra Ganatra (historical) | Director | Retired by rotation at the 25th AGM (FY2010) and eligible for reappointment | — | BSE annual report 2009–10 |
“—” = not publicly disclosed.
Major Shareholders
| Holder category | Sep 2026 |
|---|---|
Promoter & promoter group (%) | 0.00 |
Public (%) | 100.00 |
Number of shareholders | 33,026 |
Metric | FY2021 |
Number of shareholders (count, March) | 175 |
Competitive Landscape
Peer Comparison FY2024
| Metric | Amerise Biosciences (FY2024) | BAMPSL Securities (FY2024) | Century Twenty (FY2023) |
|---|---|---|---|
Net sales (INR Mn) | 0 | 84 | 17 |
Shares outstanding (M) | 66.07 | 34.04 | 2.07 |
Book value per share (INR) | 0.8 | 11.2 | 10.2 |
Average market cap (INR Mn) | 51 | 369 | 219 |
R&D intensity (%) | 0 | 0 | 0 |
Recent Developments
The company publishes no press releases, so this register is drawn from BSE filings as indexed by aggregators.
There were no contract wins, product launches, guidance revisions, litigation, layoffs or restructurings in the period.



